HTR2B and congenital bilateral aplasia of vas deferens from CFTR mutation: Future studies focused on the therapeutic potential of targeted 5-HT2B receptor blockers should include a longer time course (12–18 months) to study the impact on the later stages of CAVD where the hemodynamic, tissue, and molecular phenotypes should be stronger and interrogate the effect of 5-HT2B inhibition before and after disease onset.